278 200

Cited 48 times in

A Novel Approach to Cancer Therapy Using an Oncolytic Herpes Virus to Package Amplicons Containing Cytokine Genes

 John F. Carew  ;  David A. Kooby  ;  Marc W. Halterman  ;  Se-Heon Kim  ;  Howard J. Federoff  ;  Yuman Fong 
 MOLECULAR THERAPY, Vol.4(3) : 250-256, 2001 
Journal Title
Issue Date
Animals ; CD4-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/immunology ; Carcinoma, Squamous Cell/genetics ; Carcinoma, Squamous Cell/immunology ; Carcinoma, Squamous Cell/pathology ; Carcinoma, Squamous Cell/therapy ; Cell Death ; Cell Division ; Humans ; Immunotherapy* ; Interleukin-2/genetics* ; Interleukin-2/immunology* ; Interleukin-2/metabolism ; Interleukin-2/therapeutic use ; Mice ; Neoplasms/genetics* ; Neoplasms/immunology ; Neoplasms/pathology ; Neoplasms/therapy* ; Simplexvirus/genetics* ; Transfection ; Tumor Cells, Cultured
amplicon ; herpes simplex virus type-1 ; interleukin-2 ; oncolytic virus
There are two promising herpes viral-based anticancer strategies: one involves replication-defective viruses to transfer therapeutic transgenes, and the other involves replication-conditional oncolytic viruses, which selectively infect and destroy cancer cells directly. This study examines a novel dual herpesvirus preparation, which combines the immunostimulatory effects of amplicon-mediated IL2 expression with direct viral-induced oncolysis. The oncolytic virus G207 was used as the helper virus to package a herpes simplex virus (HSV)-amplicon vector carrying the gene IL2 (HSV-IL2), yielding a single preparation with two complementary modes of action. In vivo comparison was carried out in a syngeneic squamous cell carcinoma flank tumor model. We directly injected established tumors with HSV-IL2, G207, G207 mixed with HSV-IL2, or G207-packaged HSV-amplicon carrying the IL2 transgene (G207[IL2]). Significant inhibition of tumor growth was seen at 2 weeks in the G207[IL2]-treated tumors relative to controls (0.57plusminus0.44 cm3 versus 39.45plusminus5.13 cm3, P <0.00001), HSV-IL2 (20.97plusminus4.60 cm3), and the G207 group (7.71plusminus2.10 cm3). This unique use of a replication-conditional, oncolytic virus to package a replication-incompetent amplicon vector demonstrates impressive efficacy in vitro and in vivo, and avoids the theoretical concerns of recombination with reversion to wild type.
Files in This Item:
T200102924.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Otorhinolaryngology (이비인후과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Se Heon(김세헌)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.